Floatz logo

Tcr .Alpha..Beta. (Receptor), Anti-(Human P53 (Protein)) (Synthetic Human Single-Chain Precursor) Fusion Protein With Interleukin 2 (Human)

Malignant Renal Pelvis Neoplasm

Explore 12 assets in Malignant Renal Pelvis Neoplasm →
Floatz Rating
CCC52/100
Confidence
Indicative
v0.2
Sponsor
Altor BioScience
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT01326871CT.gov
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Malignant Renal Pelvis Neoplasm

AssetSponsorPhaseRating
Tcr .Alpha..Beta. (Receptor), Anti-(Human P53 (Protein)) (Synthetic Human Single-Chain Precursor) Fusion Protein With Interleukin 2 (Human) (this asset)Altor BioScienceP1/2CCC · 52
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Fred Hutchinson Cancer CenterP2BB
PembrolizumabFred Hutchinson Cancer CenterP2B
AtezolizumabNational Cancer Institute (NCI)P2B
ApsololEmory UniversityP2CCC
Eribulin MonomethanesulfonateNational Cancer Institute (NCI)P2CCC
RelatlimabM.D. Anderson Cancer CenterP2CCC
NivolumabM.D. Anderson Cancer CenterP2CCC
TocilizumabM.D. Anderson Cancer CenterP2CCC

+6 more in the Malignant Renal Pelvis Neoplasm cohort

Other indications for Tcr .Alpha..Beta. (Receptor), Anti-(Human P53 (Protein)) (Synthetic Human Single-Chain Precursor) Fusion Protein With Interleukin 2 (Human)

IndicationSponsorPhaseRating
Obesity Disorder—P2CCC · 53
Bladder Transitional Cell Carcinoma—P1/2CCC · 52
Urethra Cancer—P1/2CCC · 52

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Tcr .Alpha..Beta. (Receptor), Anti-(Human P53 (Protein)) (Synthetic Human Single-Chain Precursor) Fusion Protein With Interleukin 2 (Human) in Malignant Renal Pelvis Neoplasm. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/tcr-alphabeta-receptor-anti-human-p53-protein-synthetic-human-single-chain-precursor-fusion-protein-with-interleukin-2-human-malignant-renal-pelvis-neoplasm

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →